Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Bowers CY, Reynolds GA, Durham D, et al
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (surpass-1): A double-blind, randomised, phase 3 trial
Metabolic Health and Insulin Sensitivity Retatrutide demonstrates comprehensive improvements in metabolic health parameters beyond weight reduction
Weight loss medications can alter metabolic parameters, dietary patterns, hydration status, and overall health conditionsfactors that may indirectly affect the body's microbial balance
US$ 25.09
US$ 29.35
US$ 22.09
US$ 23.13
US$ 21.09
US$ 24.29
US$ 22.14
